Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CLYM Climb Bio	$1.26 -1.6%	$1.25	$1.05 ▼ $9.25	$85.15M	-0.16	272,634 shs	168,444 shs
JSPR Jasper Therapeutics	$5.58 +0.2%	$4.87	$3.13 ▼ $26.05	$83.82M	2.72	302,623 shs	151,017 shs
PVOTF BetterLife Pharma		$0.00	$0.03 ▼ $0.38	$21.70M	N/A	52,703 shs	198,200 shs
ZURA Zura Bio	$1.20 -1.6%	$1.21	$0.97 ▼ $5.07	$82.05M	-0.12	436,398 shs	246,298 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CLYM Climb Bio	0.00%	-9.35%	+5.00%	-6.67%	+125,999,900.00%
JSPR Jasper Therapeutics	0.00%	-7.15%	+14.58%	+1.64%	-76.75%
PVOTF BetterLife Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
ZURA Zura Bio	0.00%	-4.76%	0.00%	-6.25%	-67.91%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CLYM Climb Bio	3.1423 of 5 stars	3.6	0.0	0.0	0.0	2.7	2.5	1.3
JSPR Jasper Therapeutics	2.5891 of 5 stars	3.5	2.0	0.0	0.0	3.3	1.7	0.6
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	2.6343 of 5 stars	3.6	1.0	0.0	0.0	3.5	2.5	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CLYM Climb Bio	3.25	Buy	$9.00	614.29% Upside
JSPR Jasper Therapeutics	3.00	Buy	$62.22	1,015.09% Upside
PVOTF BetterLife Pharma	0.00	N/A	N/A	N/A
ZURA Zura Bio	3.13	Buy	$14.33	1,094.44% Upside

Current Analyst Ratings Breakdown

Latest PVOTF, ZURA, CLYM, and JSPR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/6/2025	CLYM Climb Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$10.00
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
5/22/2025	CLYM Climb Bio	BTIG Research Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$7.00
5/15/2025	JSPR Jasper Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$80.00 ➝ $65.00
5/13/2025	JSPR Jasper Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$38.00 ➝ $33.00
5/9/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$19.00 ➝ $17.00
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
4/3/2025	ZURA Zura Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$5.00 ➝ $3.00
3/26/2025	ZURA Zura Bio	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$20.00 ➝ $19.00
3/26/2025	ZURA Zura Bio	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/26/2025	ZURA Zura Bio	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CLYM Climb Bio	N/A	N/A	N/A	N/A	$3.90 per share	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	$7.03 per share	N/A
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	$0.01 per share	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	$1.85 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CLYM Climb Bio	-$35.12M	-$2.38	N/A	N/A	N/A	N/A	-42.21%	-41.39%	8/13/2025 (Estimated)
JSPR Jasper Therapeutics	-$64.46M	-$5.24	N/A	N/A	N/A	N/A	-67.64%	-58.53%	8/12/2025 (Estimated)
PVOTF BetterLife Pharma	-$14.78M	N/A	N/A	N/A	N/A	N/A	-205.15%	-147.23%	N/A
ZURA Zura Bio	-$69.24M	-$0.70	N/A	N/A	N/A	N/A	-37.36%	-29.81%	8/12/2025 (Estimated)

Latest PVOTF, ZURA, CLYM, and JSPR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	CLYM Climb Bio	-$0.15	-$0.31	-$0.16	-$0.31	N/A	N/A
5/12/2025	Q1 2025	JSPR Jasper Therapeutics	-$1.17	-$1.41	-$0.24	-$1.41	N/A	N/A
5/8/2025	Q1 2025	ZURA Zura Bio	-$0.17	-$0.19	-$0.02	-$0.19	N/A	N/A
3/25/2025	Q4 2024	CLYM Climb Bio	-$0.15	-$0.13	+$0.02	-$0.13	N/A	N/A
3/25/2025	Q4 2024	ZURA Zura Bio	-$0.17	-$0.08	+$0.09	-$0.08	N/A	$0.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CLYM Climb Bio	N/A	N/A	N/A	N/A	N/A
JSPR Jasper Therapeutics	N/A	N/A	N/A	N/A	N/A
PVOTF BetterLife Pharma	N/A	N/A	N/A	N/A	N/A
ZURA Zura Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CLYM Climb Bio	N/A	57.73	57.73
JSPR Jasper Therapeutics	N/A	7.61	7.61
PVOTF BetterLife Pharma	N/A	3.62	3.62
ZURA Zura Bio	N/A	10.36	10.36

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CLYM Climb Bio	69.76%
JSPR Jasper Therapeutics	79.85%
PVOTF BetterLife Pharma	N/A
ZURA Zura Bio	61.14%

Insider Ownership

Company	Insider Ownership
CLYM Climb Bio	0.80%
JSPR Jasper Therapeutics	4.60%
PVOTF BetterLife Pharma	34.77%
ZURA Zura Bio	14.23%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CLYM Climb Bio	9	67.58 million	65.07 million	N/A
JSPR Jasper Therapeutics	20	15.02 million	14.60 million	Optionable
PVOTF BetterLife Pharma	N/A	171.41 million	N/A	Not Optionable
ZURA Zura Bio	3	68.38 million	50.86 million	Optionable

PVOTF, ZURA, CLYM, and JSPR Headlines

Recent News About These Companies

Cantor Fitzgerald Weighs in on Zura Bio FY2026 Earnings

June 11, 2025 | marketbeat.com

Millennium Management LLC Has $1.75 Million Position in Zura Bio Limited (NASDAQ:ZURA)

June 3, 2025 | marketbeat.com

Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Buy" by Brokerages

May 26, 2025 | marketbeat.com

Zura Bio shareholders approve board nominees and auditor

May 24, 2025 | investing.com

HC Wainwright Issues Positive Estimate for Zura Bio Earnings

May 23, 2025 | marketbeat.com

Q1 Earnings Estimate for Zura Bio Issued By HC Wainwright

May 22, 2025 | marketbeat.com

Zura Bio commences Phase II trial of tibulizumab for hidradenitis suppurativa

May 21, 2025 | msn.com

Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa

May 20, 2025 | businesswire.com

Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates

May 9, 2025 | standard-journal.com

After losing 56% in the past year, Zura Bio Limited (NASDAQ:ZURA) institutional owners must be relieved by the recent gain

April 24, 2025 | finance.yahoo.com

Zura Bio price target lowered to $3 from $5 at H.C. Wainwright

April 4, 2025 | markets.businessinsider.com

Zura Bio (ZURA) Gets a Buy from Guggenheim

March 31, 2025 | markets.businessinsider.com

Hopeful Week For Insiders Who Bought US$1.01m Of Zura Bio Stock

March 26, 2025 | finance.yahoo.com

Zura Bio Limited: 2024 Financial Results and Strategic Progress

March 26, 2025 | tipranks.com

Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates

March 25, 2025 | businesswire.com

Zura Bio to Present at the Leerink Partners Global Healthcare Conference

February 24, 2025 | businesswire.com

ZURA stock touches 52-week low at $1.44 amid market shifts

February 11, 2025 | msn.com

Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)

January 24, 2025 | zacks.com

We Think Zura Bio (NASDAQ:ZURA) Can Afford To Drive Business Growth

January 22, 2025 | finance.yahoo.com

Zura Bio Highlights Strategic Goals and Clinical Advances

January 13, 2025 | tipranks.com

Zura Bio initiates Phase II systemic sclerosis treatment trial

December 25, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PVOTF, ZURA, CLYM, and JSPR Company Descriptions

Climb Bio NASDAQ:CLYM

$1.26 -0.02 (-1.56%)

As of 06/13/2025 04:00 PM Eastern

Climb Bio Inc. is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. The Company's lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody which has demonstrated B-cell depletion and has potential to treat a broad range of B-cell mediated diseases. Climb Bio Inc., formerly known as Eliem Therapeutics Inc., is based in WELLESLEY, Mass.

Jasper Therapeutics NASDAQ:JSPR

$5.58 +0.01 (+0.18%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$5.56 -0.02 (-0.36%)

As of 06/13/2025 07:49 PM Eastern

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy. It focuses on the development and commercialization of therapeutic agents for diseases, such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndrome, and conditioning regimens for stem cell transplantation. In addition, it is also developing stem cell transplants for rare diseases such as sickle cell disease, fanconi anemia, chronic granulomatous diseases, and GATA2 MDS, and severe combined immunodeficiency. Jasper Therapeutics, Inc. is headquartered in Redwood City, California.

BetterLife Pharma OTCMKTS:PVOTF

BetterLife Pharma, Inc. is an early stage pharmaceutical company, which engages in the development and commercialization of therapeutic pharmaceutical and nutraceutical products. It also offers drug delivery platform technologies. Its product lines include capsules, tablets, and softgels; bulk powder; stick packs; beverages; oral solutions; lotions, creams, and gels; pet food additives; gum, mints, and candies; and sexual health products. It distributes its product under the Pivot Naturals brand. The company was founded on June 10, 2002 and is headquartered in Vancouver, Canada.

Zura Bio NASDAQ:ZURA

$1.20 -0.02 (-1.64%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$1.28 +0.08 (+7.00%)

As of 06/13/2025 06:18 PM Eastern

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops Tibulizumab, an IgG-scFv bispecific dual-antagonist antibody engineered by the fusion of ixekizumab and tabalumab that neutralizes IL-17A and BAFF, which is in Phase 2 clinical trial development; ZB-168, a monoclonal antibody that binds and neutralizes the IL-7 receptor chain that impact on diseases driven by IL7 and thymic stromal lymphopoietin immune pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development. The company is based in Henderson, Nevada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time